Papillary mesothelioma of the peritoneum in the absence of asbestos exposure

Zeitschrift fur Gastroenterologie

Volumn 41, Issue 4, 2003, Pages 329-332

  Meister, T ^a   Birkfellner, T ^a   Poremba, C ^b   Becker, J C ^a   Menzel, J ^a   Domschke, W ^a   Lerch, Markus M ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

CYFRA 21 1; Immunohistochemical markers; Laparoscopy; Peritoneal mesothelioma

Indexed keywords

ASBESTOS; CYTOKERATIN; EPITHELIAL MEMBRANE ANTIGEN;

ADULT; ARTICLE; ASCITES; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; EXPOSURE; FATALITY; HISTOCHEMISTRY; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; LAPAROSCOPY; LIVER DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; OMENTUM; PERITONEAL BIOPSY; PERITONEUM MESOTHELIOMA; PORTAL HYPERTENSION; SYMPTOMATOLOGY;

ASBESTOSIS; BIOPSY; DIAGNOSIS, DIFFERENTIAL; HUMANS; LAPAROSCOPY; MALE; MESOTHELIOMA; MIDDLE AGED; PERITONEAL NEOPLASMS; PERITONEUM; TUMOR MARKERS, BIOLOGICAL;

EID: 0038372516     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-38637     Document Type: Article

References (16)

1. Neumann V, Günther S, Müller KM et al. Malignant mesothelioma German mesothelioma register 1987-1999. Int Arch Occup Environ Health 2001; 74: 383-395
2. Stefanini GF, Foschi FG, Marsigli L et al. A rare case of peritoneal mesothelioma in a male with ascites. Am J Gastroenterol 1994; 89: 2257-2259
3. Murai Y. Malignant mesothelioma in Japan: analysis of registered autopsy cases. Arch Environ Health 2001; 56 (1): 84-88
4. Amin AM, Mason C, Rowe P. Diffuse malignant mesothelioma of the peritoneum following abdominal radiotherapy. Eur J Surg Oncol 2001; 27 (2): 214-215
5. Rizzo P, Bocchetta M, Powers A et al. SV40 and the pathogenesis of mesothelioma. Semin Cancer Biol 2001; 11 (1): 63-71
6. Ascoli V, Mecucci C, Knuutila S. Genetic susceptibility and familial mesothelioma. Lancet 2001; 357 (9270): 1804
7. Ross MJ, Welch WR, Scully RE. Multilocular peritoneal inclusion cyst (multicystic mesothelioma). Cancer 1989; 64: 1336-1346
8. Daya D, McCaughey WT. Well-differentiated papillary mesothelioma of the peritoneum. Cancer 1990; 65: 292-296
9. Paganuzzi M, Onetto M, Marroni P et al. Diagnostic value of Cyfra 21 1 tumor markers and CEA in pleural effusion due to mesothelioma. Chest 2001; 119 (4): 1138-1142
10. Van Gelder T, Hoogsteden HC, Vershel MA et al. Malignant peritoneal mesothelioma: A series of 19 cases. Digestion 1989; 43: 222-227
11. Hoekman K, Tognon G, Risse EK et al. Well-differentiated papillary mesothelioma of the peritoneum: a separate entity. Eur J Cancer 1996; 322A: 255-258
12. Comin CE, Anichini C, Boddi V et al. MIB-1 proliferation index correlates with survival in pleural malignant mesothelioma. Histopathology 2000; 36: 26-31
13. Fetsch PA, Simsir A, Abati A. Comparison of antibodies to HBME-1 and calretinin for the detection of mesothelial cells in effusion cytology. Diagn Cytopathol 2001; 25: 158-161
14. Cury PM, Butcher DN, Corrin B et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 1999; 189: 251-257
15. Churg A, Colby TV, Cagle P et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 2000: 24 (9): 1183-1200
16. Sugarbaker PH, Acherman YI, Gonzalez-Moreno S et al. Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol 2002; 29 (1): 51-61